跳至主要内容
临床试验/NCT02992470
NCT02992470Unknown不适用

Hydrolyzed Oyster Extract for Liver Health: a Randomized, Double-blind, Placebo-controlled Trial

Korean Medicine Hospital of Pusan National University0 个研究点目标入组 96 人开始时间: 2016年12月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
96
主要终点
Change of serum alanine aminotransferase (ALT)

研究概览

简要总结

This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal. A total of 96 participants will be randomly allocated to active (oyster) or placebo group (1:1). Each group will receive 750 mg of oyster extract or placebo per day for 8 weeks. Primary outcome will be the change in ALT level and secondary outcomes will be; (1) ratios of participants with normal ALT, aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT); (2) the change in serum bilirubin; (3) the change in multi-dimensional fatigue inventory; (4) the changes in serum lipids; (5) the changes in antioxidant enzymes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age over 19
  • AST, ALT, and GGT levels above the upper limit of the normal but less than 3 times the upper limit of the normal
  • Participants with normal physical activity who sign an informed consent form
  • Fatty liver detected by ultrasound

排除标准

  • Allergic reaction to oyster
  • Uncontrolled diabetes mellitus
  • Active viral hepatitis and any liver diseases that can affect trial outcomes (positive for HBs Ag or HCV Ab)
  • Liver cirrhosis of Child-Pugh class B or C
  • Chemotherapy or radiation therapy for cancer within 6 months
  • Cholelithiasis
  • Systemic medications that can affect liver function such as INH, valproic acid, tetracycline, allopurinol, phenytoin, phenelzine, sertraline, naproxen and diclofenac within 4 weeks
  • Medication of cholagogues, cholelitholytics & hepatic protectors, antidotes, detoxifying agents, and drug abuse (drugs used in substance dependence) within 4 weeks
  • Alcoholism or excessive alcohol intake of more than 168 g/week in men and 112 g/week in women
  • Kidney diseases or serum creatinine level above 2.0 mg/dL
  • Uncontrolled hypertension or angina pectoris or myocardiac infarction
  • History of bowel resection (not including surgery on simple appendicitis)
  • Medication of antipsychotic drugs
  • Herbal medication within 2 months
  • Pregnancy or breastfeeding
  • Participation of other clinical trial(s) within 1 months from screening day
  • Uncooperativeness
  • Intake of dietary supplements within 4 weeks

结局指标

主要结局

Change of serum alanine aminotransferase (ALT)

时间窗: Baseline, 4 weeks and 8 weeks

次要结局

  • Change of serum aspartate aminotransferase (AST)(Baseline, 4 weeks and 8 weeks)
  • Change of gamma-glutamyl transferase (GGT)(Baseline, 4 weeks and 8 weeks)
  • Rate of participants with normalized ALT, AST and GGT(Baseline, 4 weeks and 8 weeks)
  • Change of serum bilirubin(Baseline, 4 weeks and 8 weeks)
  • Change of multi-dimensional fatigue inventory(Baseline, 4 weeks and 8 weeks)
  • Change of serum lipid profiles (triglyceride, total cholesterol, High-density lipoprotein and low-density lipoprotein cholesterol)(Baseline, 4 weeks and 8 weeks)
  • Change of antioxidant enzymes (superoxide dismutase, malondialdehyde, glutathione peroxidase)(Baseline, 4 weeks and 8 weeks)

研究者

发起方
Korean Medicine Hospital of Pusan National University
申办方类型
Other
责任方
Sponsor

相似试验